



Momenta Pharmaceuticals to Present at Stanford Group Company 13th Annual Healthcare Conference

CAMBRIDGE, Mass., Jan 15, 2008 (PrimeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Richard Shea, Chief Financial Officer, will deliver a corporate presentation at the Stanford Group Company 13th Annual Healthcare Conference on Thursday, January 17th at 10:30 a.m. EST. The conference will be held at The Four Seasons Hotel in Washington, D.C.

A live audio webcast of each presentation will be available on the "Investors" section of the Company's website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately thirty minutes after the event and will be available through February 16th, 2008.

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. The Company's most advanced product candidate, M-Enoxaparin is designed to be a technology-enabled generic version of Lovenox(r). Momenta's first novel drug candidate is M118, a rationally engineered anticoagulant specifically designed for acute coronary syndromes. Within the Company's discovery program, it is seeking to discover and develop novel therapeutics by applying its technology to better understand sugars' functions in biological processes, with an initial focus in oncology. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA.

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc.
Investor Relations
Beverly Holley
617-395-5189

(C) Copyright 2007 PrimeNewswire, Inc. All rights reserved.

News Provided by COMTEX